8-K/A: XOMA Royalty Corp Amends 8-K to Include Pulmokine Financials After $20 Million Acquisition

XOMA Royalty Corporation files an amendment to its original Form 8-K to include historical financial statements of Pulmokine, Inc., following its acquisition for $20 million.

Summary

• XOMA Royalty Corporation filed an amendment to its original Form 8-K to include Pulmokine's historical financial statements and pro forma financial information.
• This follows XOMA's acquisition of Pulmokine for $20 million in cash, completed on November 26, 2024.
• The amendment includes Pulmokine's audited financial statements for the year ended December 31, 2023, and unaudited financial statements for the nine months ended September 30, 2024.
• Pro forma financial information, reflecting the combined entity, is also included for the same periods.
• The acquisition was financed with cash on hand.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the acquisition itself is a positive move for XOMA, the inclusion of Pulmokine's financials reveals a recent net loss. The future potential of Seralutinib royalties is a positive factor, but the overall impact is uncertain.

Positives

• Pulmokine generated $10 million in revenue and a net income of $7,948,814 for the year ended December 31, 2023.
• The acquisition provides XOMA with rights to future milestone and royalty payments under Pulmokine's license agreement with Gossamer Bio related to Seralutinib.

Negatives

• Pulmokine reported a net loss of $567,753 for the nine months ended September 30, 2024.
• Pulmokine had an accumulated deficit of $2,547,650 as of September 30, 2024.

Risks

• The pro forma financial information is not necessarily indicative of the future financial position or operating results of the combined operations.
• The pro forma information does not reflect the costs of any integration activities or benefits that may result from realization of future cost savings from operating efficiencies or revenue synergies expected to result from the Transaction.
• Preliminary fair value estimates may change as additional information becomes available.

Future Outlook

The transaction primarily provides XOMA with rights to future milestone and royalty payments under Pulmokines License Agreement with Gossamer Bio related to the development and commercialization of Seralutinib, a clinical-stage product candidate. XOMA Royaltys net royalties will range from the low to mid-single digits on commercial sales; additionally, the Company will retain up to $25 million of the milestone payments

Industry Context

The acquisition of Pulmokine by XOMA Royalty Corporation reflects a trend in the biopharmaceutical industry where companies acquire promising assets or technologies to expand their portfolios and revenue streams. Royalty companies like XOMA often seek to acquire rights to future royalties and milestone payments from drugs in development, providing them with potential long-term revenue.

Comparison to Industry Standards

• It's difficult to directly compare this acquisition to industry standards without knowing the specific terms of the royalty agreement and the potential market for Seralutinib.
• However, similar deals in the royalty space often involve upfront payments plus contingent milestone payments based on clinical and commercial success.
• Comparable companies in the royalty space include DRI Healthcare Trust and Ligand Pharmaceuticals, which also acquire royalty streams from pharmaceutical products.

Related Party Transactions

• Pulmokine had a consulting agreement with T2M Pathways, Inc., a company owned by Pulmokine's Executive Chair, with expenses of $50,000 in 2023 and $74,000 for the nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders of XOMA may see potential long-term benefits from the acquisition of Pulmokine's assets.
• Employees of Pulmokine are now part of XOMA Royalty Corporation.
• Gossamer Bio, as the licensee of Seralutinib, will continue its development and commercialization efforts, potentially impacting future royalty payments to XOMA.

Next Steps

• XOMA will integrate Pulmokine's assets and rights into its existing portfolio.
• XOMA will monitor the progress of Seralutinib's development and commercialization by Gossamer Bio to realize potential milestone and royalty payments.

Key Dates

Keywords

acquisition, Pulmokine, XOMA, financial statements, pro forma, merger, royalty, Seralutinib, biopharmaceutical